{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:39:47Z","timestamp":1793147987096,"version":"4.5.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2008255"],"award-info":[{"award-number":["2008255"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rmed.2025.108353","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T18:08:15Z","timestamp":1758132495000},"page":"108353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Treatable traits in interstitial lung disease: opportunities and challenges"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-9342","authenticated-orcid":false,"given":"Yet H.","family":"Khor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna J.","family":"Podolanczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta A.","family":"Renzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Strek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rmed.2025.108353_bib1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/thoraxjnl-2020-216732","article-title":"Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the global Burden of disease study 2019","volume":"77","author":"Ma","year":"2022","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.rmed.2025.108353_bib2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1183\/13993003.01204-2015","article-title":"European IPF patient charter: unmet needs and a call to action for healthcare policymakers","volume":"47","author":"Bonella","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"156","key":"10.1016\/j.rmed.2025.108353_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0125-2019","article-title":"The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review","volume":"29","author":"Lee","year":"2020","journal-title":"Eur. Respir. Rev."},{"issue":"6","key":"10.1016\/j.rmed.2025.108353_bib5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/thoraxjnl-2020-215731","article-title":"Top 10 research priorities for people living with pulmonary fibrosis, their caregivers, healthcare professionals and researchers","volume":"76","author":"Tikellis","year":"2021","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib6","article-title":"Research priorities for progressive pulmonary fibrosis in the UK","volume":"11","author":"Fabbri","year":"2024","journal-title":"BMJ Open Respir Res."},{"issue":"9743","key":"10.1016\/j.rmed.2025.108353_bib7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(10)61087-2","article-title":"Asthma in older adults","volume":"376","author":"Gibson","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01269-2018","article-title":"Treatable traits in bronchiectasis","volume":"52","author":"Boaventura","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jsmc.2021.05.005","article-title":"Future treatment of sleep disorders: syndromic approach versus management of treatable traits?","volume":"16","author":"Pevernagie","year":"2021","journal-title":"Sleep Med. Clin."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2213-2600(23)00002-4","article-title":"Treatable traits in interstitial lung diseases: a call to action","volume":"11","author":"Amati","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00404-2023","article-title":"Treatable traits: a comprehensive precision medicine approach in interstitial lung disease","volume":"62","author":"Khor","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108353_bib13","doi-asserted-by":"crossref","DOI":"10.1213\/ANE.0000000000006727","article-title":"Subphenotypes in acute respiratory distress syndrome: universal steps toward treatable traits","author":"Filippini","year":"2024","journal-title":"Anesth. Analg."},{"issue":"5","key":"10.1016\/j.rmed.2025.108353_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02058-2018","article-title":"Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits Down under international workshop report","volume":"53","author":"McDonald","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.rmed.2025.108353_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5694\/mja2.51464","article-title":"Treatable traits in asthma: moving beyond diagnostic labels","volume":"216","author":"McDonald","year":"2022","journal-title":"Med. J. Aust."},{"issue":"12","key":"10.1016\/j.rmed.2025.108353_bib16","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1513\/AnnalsATS.202303-188PS","article-title":"Approach to clinical trials for the prevention of pulmonary fibrosis","volume":"20","author":"Kim","year":"2023","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2025.108353_bib17","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202505-1054ST","article-title":"Approach to the evaluation and management of interstitial lung abnormalities. An official American thoracic society clinical statement","author":"Podolanczuk","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.rmed.2025.108353_bib18","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1164\/rccm.202403-0524OC","article-title":"Progressive early interstitial lung abnormalities in persons at risk for familial pulmonary fibrosis: a prospective cohort study","volume":"210","author":"Salisbury","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108353_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1164\/rccm.202206-1075OC","article-title":"Incidence and progression of fibrotic lung disease in an At-Risk cohort","volume":"207","author":"Steele","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"23","key":"10.1016\/j.rmed.2025.108353_bib20","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in U.S. deaths from coronary disease, 1980-2000","volume":"356","author":"Ford","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.108353_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.202108-1967OC","article-title":"Associations of monocyte count and other immune cell types with interstitial lung abnormalities","volume":"205","author":"Kim","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1164\/rccm.202003-0669OC","article-title":"Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis","volume":"204","author":"Kreuter","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European respiratory society\/American thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2025.108353_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01205-2020","article-title":"Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype","volume":"56","author":"Graham","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.chest.2022.06.013","article-title":"Integration and application of clinical practice guidelines for the diagnosis of idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis","volume":"162","author":"Marinescu","year":"2022","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1183\/09031936.01.17101220","article-title":"Smoking-related interstitial lung diseases: a concise review","volume":"17","author":"Ryu","year":"2001","journal-title":"Eur. Respir. J."},{"issue":"125","key":"10.1016\/j.rmed.2025.108353_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1183\/09059180.00003112","article-title":"An integrated approach in the diagnosis of smoking-related interstitial lung diseases","volume":"21","author":"Caminati","year":"2012","journal-title":"Eur. Respir. Rev."},{"issue":"163","key":"10.1016\/j.rmed.2025.108353_bib28","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0169-2021","article-title":"Diagnosis, course and management of hypersensitivity pneumonitis","volume":"31","author":"Hamblin","year":"2022","journal-title":"Eur. Respir. Rev."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1164\/rccm.202409-1730PP","article-title":"Impact of environmental exposures on the development and progression of fibrotic interstitial lung disease","volume":"211","author":"Johannson","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10429","key":"10.1016\/j.rmed.2025.108353_bib30","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"issue":"10429","key":"10.1016\/j.rmed.2025.108353_bib31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","article-title":"Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial","volume":"403","author":"Rech","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.rmed.2025.108353_bib32","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.12-2685","article-title":"Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis","volume":"144","author":"Fernandez Perez","year":"2013","journal-title":"Chest"},{"issue":"25","key":"10.1016\/j.rmed.2025.108353_bib33","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.rmed.2025.108353_bib34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.108353_bib36","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.rmed.2025.108353_bib37","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"American college of rheumatology (ACR)\/American college of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.rmed.2025.108353_bib38","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","author":"Spagnolo","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1148\/rg.210146","article-title":"Medication-induced pulmonary injury: a Scenario- and pattern-based approach to a perplexing problem","volume":"42","author":"Sridhar","year":"2022","journal-title":"Radiographics"},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00756-2024","article-title":"Diffuse lung diseases ascribed to drugs: a nationwide observational study over 37 years using the French pharmacovigilance database","volume":"65","author":"Yavordios","year":"2025","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.rmed.2025.108353_bib41","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1164\/rccm.202112-2742SO","article-title":"Autoimmune pulmonary alveolar proteinosis","volume":"205","author":"McCarthy","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12890-025-03611-2","article-title":"Polypharmacy and potentially inappropriate medication (PIM) use among older veterans with idiopathic pulmonary fibrosis (IPF) - a retrospective cohort study","volume":"25","author":"Guidot","year":"2025","journal-title":"BMC Pulm. Med."},{"issue":"6","key":"10.1016\/j.rmed.2025.108353_bib43","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/resp.13480","article-title":"Therapeutic burden in interstitial lung disease: lessons to learn","volume":"24","author":"Khor","year":"2019","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.rmed.2025.108353_bib44","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1513\/AnnalsATS.202108-980OC","article-title":"Impact of concomitant medication burden on tolerability of disease-targeted therapy and survival in interstitial lung disease","volume":"19","author":"Khor","year":"2022","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"22","key":"10.1016\/j.rmed.2025.108353_bib45","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.rmed.2025.108353_bib46","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.rmed.2025.108353_bib47","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40264-020-00978-5","article-title":"Anticoagulant use and bleeding risk in central European patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotic therapy: real-world data from EMPIRE","volume":"43","author":"Kolonics-Farkas","year":"2020","journal-title":"Drug Saf."},{"issue":"S2","key":"10.1016\/j.rmed.2025.108353_bib48","article-title":"Bleeding risk in patients with idiopathic pulmonary fibrosis (IPF) on nintedanib and con-current anticoagulation or antiplatelet therapy","volume":"74","author":"Denneny","year":"2019","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib49","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0123-2023","article-title":"The role of the clinical pharmacist in the respiratory or sleep multidisciplinary team","volume":"19","author":"Clements","year":"2023","journal-title":"Breathe"},{"issue":"5","key":"10.1016\/j.rmed.2025.108353_bib50","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1378\/chest.13-0806","article-title":"Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia","volume":"144","author":"Wallaert","year":"2013","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.rmed.2025.108353_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277973","article-title":"Physical activity pattern of patients with interstitial lung disease compared to patients with COPD: a propensity-matched study","volume":"17","author":"Breuls","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12890-017-0444-0","article-title":"Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis","volume":"17","author":"Bahmer","year":"2017","journal-title":"BMC Pulm. Med."},{"issue":"11","key":"10.1016\/j.rmed.2025.108353_bib53","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jsams.2022.10.002","article-title":"Physical activity, exercise capacity and mortality risk in people with interstitial lung disease: a systematic review and meta-analysis","volume":"25","author":"Rocha","year":"2022","journal-title":"J. Sci. Med. Sport"},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib54","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1164\/rccm.202306-1066ST","article-title":"Pulmonary rehabilitation for adults with chronic respiratory disease: an official American thoracic society clinical practice guideline","volume":"208","author":"Rochester","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib55","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"2","author":"Dowman","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.rmed.2025.108353_bib56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.hrtlng.2023.02.018","article-title":"Lifestyle integrated functional exercise for people with interstitial lung disease (iLiFE): a mixed-methods feasibility study","volume":"60","author":"Paix\u00e3o","year":"2023","journal-title":"Heart Lung"},{"key":"10.1016\/j.rmed.2025.108353_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.pecinn.2024.100328","article-title":"A self-management package for pulmonary fibrosis: a feasibility study","volume":"5","author":"Lee","year":"2024","journal-title":"PEC Innov."},{"issue":"170","key":"10.1016\/j.rmed.2025.108353_bib58","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0092-2023","article-title":"Self-management interventions for people with pulmonary fibrosis: a scoping review","volume":"32","author":"Lee","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2025.108353_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/14799731241235231","article-title":"Physical activity coaching in patients with interstitial lung diseases: a randomized controlled trial","volume":"21","author":"Breuls","year":"2024","journal-title":"Chron. Respir. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib60","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1164\/rccm.202206-1041ST","article-title":"Syndrome of combined pulmonary fibrosis and emphysema: an official ATS\/ERS\/JRS\/ALAT research statement","volume":"206","author":"Cottin","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.rmed.2025.108353_bib61","first-page":"8617","article-title":"Clinical efficacy and safety of ICS\/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema","volume":"8","author":"Dong","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib62","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1183\/09031936.00099910","article-title":"Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis","volume":"39","author":"Noth","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib63","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1183\/13993003.01796-2015","article-title":"Hiatal hernia on thoracic computed tomography in pulmonary fibrosis","volume":"48","author":"Tossier","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2025.108353_bib64","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02412-2018","article-title":"In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality","volume":"53","author":"Mackintosh","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108353_bib66","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1513\/AnnalsATS.202102-172OC","article-title":"Antacid medication and antireflux surgery in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"19","author":"Khor","year":"2022","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2025.108353_bib67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1477-7525-3-61","article-title":"Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives","volume":"3","author":"Swigris","year":"2005","journal-title":"Health Qual. Life Outcome"},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib68","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00039-2023","article-title":"Understanding patient experience of chronic cough in interstitial lung disease","volume":"9","author":"Mann","year":"2023","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.rmed.2025.108353_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107659","article-title":"Patient and caregiver shared experiences of pulmonary fibrosis (PF): a systematic literature review","volume":"227","author":"Wells","year":"2024","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib70","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12931-020-01421-0","article-title":"Trends and seasonal variation of hospitalization and mortality of interstitial lung disease in the United States from 2006 to 2016","volume":"21","author":"Ho","year":"2020","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib71","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00628-2018","article-title":"The potential impact of azithromycin in idiopathic pulmonary fibrosis","volume":"53","author":"Macaluso","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib72","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02571-2021","article-title":"Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry","volume":"60","author":"Hambly","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib73","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02718-2020","article-title":"Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)","volume":"57","author":"Nasser","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib74","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib76","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1164\/rccm.202401-0048PP","article-title":"The role of inflammation and fibrosis in interstitial lung disease treatment decisions","volume":"210","author":"Behr","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.108353_bib77","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","author":"Maher","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108353_bib78","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in patients with idiopathic pulmonary fibrosis","author":"Richeldi","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib79","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12890-024-02929-7","article-title":"Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients","volume":"24","author":"Nili","year":"2024","journal-title":"BMC Pulm. Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.108353_bib80","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1007\/s12325-021-01768-w","article-title":"Effect of a patient support program for idiopathic pulmonary fibrosis patients on medication persistence: a retrospective database analysis","volume":"38","author":"Near","year":"2021","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12325-015-0183-7","article-title":"IPF care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe","volume":"32","author":"Duck","year":"2015","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib82","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00262-2023","article-title":"Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial","volume":"62","author":"Molina-Molina","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib83","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.chest.2024.04.025","article-title":"Pulmonary hypertension in interstitial lung disease: a systematic review and meta-analysis","volume":"166","author":"Ang","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib84","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01311-2017","article-title":"A scoring system to predict the elevation of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis","volume":"51","author":"Furukawa","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib85","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib86","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00115-2022","article-title":"Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges","volume":"8","author":"Kewalramani","year":"2022","journal-title":"ERJ Open Res."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib87","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S2213-2600(17)30478-2","article-title":"Patients with IPF and lung cancer: diagnosis and management","volume":"6","author":"Tzouvelekis","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"175","key":"10.1016\/j.rmed.2025.108353_bib88","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0238-2024","article-title":"Comorbidities in the idiopathic pulmonary fibrosis and progressive pulmonary fibrosis trial population: a systematic review and meta-analysis","volume":"34","author":"Walters","year":"2025","journal-title":"Eur. Respir. Rev."},{"issue":"7","key":"10.1016\/j.rmed.2025.108353_bib89","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tcm.2017.04.004","article-title":"Incidental coronary calcifications on routine chest CT: clinical implications","volume":"27","author":"Pakdaman","year":"2017","journal-title":"Trends Cardiovasc. Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108353_bib90","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1378\/chest.06-2784","article-title":"Body mass index and mortality in patients with idiopathic pulmonary fibrosis","volume":"131","author":"Alakhras","year":"2007","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib91","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00037-2021","article-title":"Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"7","author":"Awano","year":"2021","journal-title":"ERJ Open Res."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62572-4","article-title":"Body mass index is associated with clinical outcomes in idiopathic pulmonary fibrosis","volume":"14","author":"Yoon","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmed.2025.108353_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106792","article-title":"Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD","volume":"195","author":"Schaeffer","year":"2022","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108353_bib94","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/MCP.0000000000000697","article-title":"Obstructive sleep apnea in pulmonary fibrosis","volume":"26","author":"Schiza","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.rmed.2025.108353_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101442","article-title":"Interstitial lung disease and obstructive sleep apnea","volume":"58","author":"Khor","year":"2021","journal-title":"Sleep Med. Rev."},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib96","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17476348.2025.2453657","article-title":"Challenges of symptom management in interstitial lung disease: dyspnea, cough, and fatigue","volume":"19","author":"Pascoe","year":"2025","journal-title":"Expet Rev. Respir. Med."},{"issue":"8","key":"10.1016\/j.rmed.2025.108353_bib97","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1164\/rccm.202311-2101OC","article-title":"Epidemiology and prognostic significance of cough in fibrotic interstitial lung disease","volume":"210","author":"Khor","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib98","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.21037\/apm-24-7","article-title":"Chronic breathlessness in fibrotic interstitial lung diseases-patient centered assessment and management in outpatient settings","volume":"13","author":"Kalluri","year":"2024","journal-title":"Ann. Palliat. Med."},{"issue":"10","key":"10.1016\/j.rmed.2025.108353_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph14101277","article-title":"Psycho-physiological associates of dyspnea in hospitalized patients with interstitial lung diseases: a cross-sectional study","volume":"14","author":"Zhou","year":"2017","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"6","key":"10.1016\/j.rmed.2025.108353_bib100","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00335-2024","article-title":"European respiratory society clinical practice guideline on symptom management for adults with serious respiratory illness","volume":"63","author":"Holland","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14010291","article-title":"Examining cough's role and relief strategies in interstitial lung disease","volume":"14","author":"Lim","year":"2025","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib102","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S2213-2600(23)00432-0","article-title":"Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial","volume":"12","author":"Wu","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.rmed.2025.108353_bib103","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300083","article-title":"Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis","volume":"2","author":"Maher","year":"2023","journal-title":"NEJM Evid"},{"issue":"9853","key":"10.1016\/j.rmed.2025.108353_bib105","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0140-6736(12)60776-4","article-title":"Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Ryan","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib106","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1378\/chest.15-1271","article-title":"Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial","volume":"149","author":"Vertigan","year":"2016","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib107","first-page":"389","article-title":"A non-pharmacological cough therapy for people with interstitial lung diseases: a case report","volume":"75","author":"Dasouki","year":"2023","journal-title":"Physiother. Can."},{"issue":"165","key":"10.1016\/j.rmed.2025.108353_bib108","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0042-2022","article-title":"Does pulmonary rehabilitation address treatable traits? A systematic review","volume":"31","author":"Holland","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2025.108353_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.resp.2023.104041","article-title":"Physiological underpinnings of exertional dyspnoea in mild fibrosing interstitial lung disease","volume":"312","author":"Smyth","year":"2023","journal-title":"Respir. Physiol. Neurobiol."},{"issue":"12","key":"10.1016\/j.rmed.2025.108353_bib110","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","article-title":"Palliative care in interstitial lung disease: living well","volume":"5","author":"Kreuter","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib111","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/resp.14185","article-title":"Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia","volume":"27","author":"Tikellis","year":"2022","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib112","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41514-023-00132-2","article-title":"Attitudes and barriers towards deprescribing in older patients experiencing polypharmacy: a narrative review","volume":"10","author":"Robinson","year":"2024","journal-title":"NPJ Aging"},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib113","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000492937","article-title":"Efficacy and safety of pirfenidone in advanced idiopathic pulmonary fibrosis","volume":"97","author":"Yoon","year":"2019","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib114","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12931-018-0907-8","article-title":"Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis","volume":"19","author":"Yoon","year":"2018","journal-title":"Respir. Res."},{"issue":"5","key":"10.1016\/j.rmed.2025.108353_bib115","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s12325-020-01328-8","article-title":"Safety and efficacy of pirfenidone in advanced idiopathic pulmonary fibrosis: a nationwide post-marketing surveillance study in Korean patients","volume":"37","author":"Chung","year":"2020","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib116","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01289-2018","article-title":"Weight loss as a predictor of mortality in patients with interstitial lung disease","volume":"52","author":"Pugashetti","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2025.108353_bib117","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.chest.2021.11.008","article-title":"Association of BMI and change in weight with mortality in patients with fibrotic interstitial lung disease","volume":"161","author":"Comes","year":"2022","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2025.108353_bib118","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/s41598-023-32843-7","article-title":"Clinical impact of weight loss on mortality in patients with idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"13","author":"Lee","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmed.2025.108353_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2022.111964","article-title":"A 1-year follow-up study in patients with idiopathic pulmonary fibrosis regarding adverse outcomes to unintended weight loss","volume":"108","author":"Holst","year":"2023","journal-title":"Nutrition"},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078608","article-title":"Eating and drinking experience in patients with idiopathic pulmonary fibrosis: a qualitative study","volume":"14","author":"Alamer","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmed.2025.108353_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101839","article-title":"Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis","volume":"59","author":"Perelas","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2025.108353_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2023.102213","article-title":"Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis","volume":"80","author":"Tomioka","year":"2023","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib123","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.resinv.2024.04.011","article-title":"Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease","volume":"62","author":"Yamakawa","year":"2024","journal-title":"Respir Investig."},{"issue":"6","key":"10.1016\/j.rmed.2025.108353_bib124","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1513\/AnnalsATS.201611-934OC","article-title":"Oxygen therapy for interstitial lung disease. A mismatch between patient expectations and experiences","volume":"14","author":"Khor","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"169","key":"10.1016\/j.rmed.2025.108353_bib125","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0066-2023","article-title":"Barriers to and facilitators of the use of oxygen therapy in people living with an interstitial lung disease: a systematic review of qualitative evidence","volume":"32","author":"Tikellis","year":"2023","journal-title":"Eur. Respir. Rev."},{"issue":"12","key":"10.1016\/j.rmed.2025.108353_bib126","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1513\/AnnalsATS.202303-208OC","article-title":"Predicting new-onset exertional and resting hypoxemia in fibrotic interstitial lung disease","volume":"20","author":"Saleem","year":"2023","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"6","key":"10.1016\/j.rmed.2025.108353_bib127","doi-asserted-by":"crossref","first-page":"667","DOI":"10.4187\/respcare.09446","article-title":"Multidisciplinary care and prognosis in patients with COPD and interstitial lung disease prescribed long-term oxygen therapy","volume":"67","author":"Harrison","year":"2022","journal-title":"Respir. Care"},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2025.108353_bib128","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-206865","article-title":"British thoracic society guidelines for home oxygen use in adults","volume":"70","author":"Hardinge","year":"2015","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.rmed.2025.108353_bib129","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1164\/rccm.202009-3608ST","article-title":"Home oxygen therapy for adults with chronic lung disease. An official American thoracic society clinical practice guideline","volume":"202","author":"Jacobs","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.rmed.2025.108353_bib130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/resp.14793","article-title":"Thoracic society of Australia and New Zealand clinical practice guideline on adult home oxygen therapy","volume":"29","author":"McDonald","year":"2024","journal-title":"Respirology"},{"issue":"10","key":"10.1016\/j.rmed.2025.108353_bib131","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2025.108353_bib132","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A2907","article-title":"Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised sham-controlled trial","volume":"211","author":"Holland","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib133","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-93-3-391","article-title":"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal oxygen therapy trial group","volume":"93","year":"1980","journal-title":"Ann. Intern. Med."},{"issue":"8222","key":"10.1016\/j.rmed.2025.108353_bib134","first-page":"681","article-title":"Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the medical research council working party","volume":"1","year":"1981","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rmed.2025.108353_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0297832","article-title":"A scoping review of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis (IPF)","volume":"19","author":"Bramhill","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib136","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.hrtlng.2009.08.005","article-title":"Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners","volume":"39","author":"Lindell","year":"2010","journal-title":"Heart Lung"},{"issue":"4","key":"10.1016\/j.rmed.2025.108353_bib137","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01596-2016","article-title":"Patient and partner empowerment programme for idiopathic pulmonary fibrosis","volume":"49","author":"van Manen","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2025.108353_bib138","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/resp.14859","article-title":"A digital therapy targeting anxiety in pulmonary fibrosis: a decentralized randomized controlled trial","volume":"30","author":"Solomon","year":"2025","journal-title":"Respirology"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125004160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125004160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:07:33Z","timestamp":1761116853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125004160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":137,"alternative-id":["S0954611125004160"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108353","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatable traits in interstitial lung disease: opportunities and challenges","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108353"}}